Luminogenic cytochrome P450 assays

Expert Opinion on Drug Metabolism and Toxicology

Volumn 2, Issue 4, 2006, Pages 629-645

  Cali, James J ^a   Ma, Dongping ^a   Sobol, Mary ^a   Simpson, Daniel J ^a   Frackman, Susan ^a   Good, Troy D ^b   Daily, William J ^b   Liu, David ^c  

^a PROMEGA CORPORATION   (United States)

^b Promega Biosciences Inc   (United States)

^c INTEL CORPORATION   (United States)

Author keywords

CYP; CYP induction; CYP inhibition; Cytochrome P450; Drug metabolism; Drug drug interaction; Fluorescent P450 assay; Hepatocyte; High throughput screening; Liver microsomes; Luminescent P450 assay; P450 Glo ; Recombinant CYP enzymes

Indexed keywords

ASTEMIZOLE; CERIVASTATIN; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A7; CYTOCHROME P450 4A11; FIREFLY LUCIFERASE; MIBEFRADIL; TERFENADINE; ENZYME INHIBITOR; FLUORESCENT DYE; LUCIFERASE; LUMINESCENT AGENT;

CELL CULTURE; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; LIVER CELL; LIVER MICROSOME; RADIOASSAY; REVIEW; ALGORITHM; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; ENZYME SPECIFICITY; METABOLISM;

ALGORITHMS; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FLUORESCENT DYES; HUMANS; LUCIFERASES; LUMINESCENT AGENTS; SUBSTRATE SPECIFICITY;

EID: 33747828962     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2.4.629     Document Type: Review

References (84)

1. WRIGHTON SA, STEVENS JC: The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Tox. (1992) 22(1):1-21.
2. BJORNSSON TD, CALLAHAN JT, EINOLF HJ et al.: The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. (2003) 31(7):815-832. A widely referenced guidance manual for in vitro DDI studies.
3. PELKONEN O: Human CYPs: in vivo and clinical aspects. Drug Metab. Rev. (2002) 34(1&2):37-46.
4. WEINKERS LC, HEATH GH: Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Disc. (2005) 4:825-833. An excellent overview of the principles of in vitro metabolism and DDI work.
5. ZLOKARNIK G, GROOTENHUIS PDJ, WATSON JB: High throughput P450 screens in early drug discovery. Drug Disc. Today (2005) 10(21):1443-1450.
6. FRIEDMAN MA, WOODCOCK JL, LUMPKIN MM, SHUREN JE, HASS AE, THOMPSON I.J: The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA (1999) 281(18):1728-1734.
7. LIN JH: Species similarities and differences in pharmacokinetics. Drug Metab. Dispos. (1995) 23(10):1008-1021.
8. WILLIAMS JA, HYLAND R, JONES BC et al.: Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUC/AUC) ratios. Drug Metab. Dispos. (2004) 32(11):1201-1208.
9. FURGE LL, GUENGERICH FP: Cytochrome P450 enzymes in drug metabolism and chemical toxicity. Biochem. Mol. Biol. Ed. (2006) 34(2):66-74.
10. VERMIER M, ANNAERT P, MAMIDI RNVS, ROYMANS D, MEULDERMANS W, MANNENS G: Cell-based models to study hepatic drug metabolism and enzyme induction in humans. Expert Opin. Drug Metab. Toxicol. (2005) 1(1):75-90.
11. YUEY M-F, KAWAHARA M, RAUCY J: High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line. Drug Metab Dispos. (2005) 33(1):38-48.
12. MILLS BM, ROSE KA, SADAGOPAN N, SAHI J, MORAIS SMF: Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J. Pharm. Exp. Ther. (2004) 309(1):303-309.
13. KELLY JH, SUSSMAN NL: A fluorescent cell-based assay for cytochrome P450 isozyme 1A2 induction and inhibition. J. Biomol. Screen. (2000) 5(4):249-254.
14. MADAN A, GRAHAM RA, CARROLL KM et al.: Effects of prototypical enzyme inducers on cytochrome P450 expression in cultured hepatocytes. Drug Metab. Dispos. (2003) 31(4):421-431.
15. WILLSON TM, KLIEWER SA: PXR, CAR and drug metabolism. Nat. Rev. Drug Disc. (2002) 1:259-266.
16. FERGUSON SS, CHEN Y, LECLUYSE EL, GOLDSTEIN JA: Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4-α. Mol. Pharmacol. (2005) 68(3):747-757.
17. CHEN Y, FERGUSON SS, NEGISGI M, GOLDSTEIN JA: Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol. Pharmacol. (2003) 64(2):316-324.
18. NEBERT DW, ROE AL, DIETER MZ, SOLIS WA, YANG Y, DALTON TP: Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem. Pharm. (1999) 59:65-85.
19. SAVAS U, HSU MH, JOHNSON EF: Differential regulation of human CYP4A genes by peroxisome proliferators and dexamethasone. Arch. Biochem. Biophys. (2003) 409(1):212-220.
20. TANG W, WANG RW, LU, AYH: Utility of recombinant cytochrome P450 enzymes: a drug metabolism perspective. Curr. Drug Metab. (2005) 6:503-517.
21. SEGEL IH: Enzyme kinetics. John Wiley & Sons, Canada (1975). A classic text on rapid equilibrium and steady-state enzyme systems.
22. ITO K, IWATSUBO T, KANAMITSU S, NAKAJIMA Y, SUGIYAMA Y: Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Ann. Rev. Pharmacol. Toxicol. (1998) 38:461-499. A good description of how in vitro data is used to predict in vivo effects.
23. BRANCHINI BR, MAGYAR RA, MURTIASHAW MH, ANDERSON SM, ZIMMER M: Site-directed mutagenesis of histidine 245 in firefly luciferase: a proposed model of the active site. Biochemistry (1998) 37(44):15311-15319.
24. WORZELLA T, LARSON B, CALI J, GALLAGHER A, MATTHEWS E: Miniaturizing luminescent P450-Glo™ assays for HTS. Cell Notes (2004) 10:6-8.
25. GUENGERICH FP: Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. (2001) 14(6):611-650. An excellent review of the CYP reaction cycle and reaction mechanisms.
26. CALI JJ, HO S, MA D et al.: Bioluminescent P450 assays that use D-luciferin derivatives as substrates for CYP1A1, 1A2, 1B1, 2C8, 2C9, 2J2, 3A4, 3A7,4A11, 4F3B, 4F12 and 19. Proceedings of the 14th International Conference on Cytochrome P450s-Medimond S.r.l. International Proceedings. (2005):77-84.
27. CALI JJ, SOBOL M, MA D, GOOD T, LIU D: P450-Glo™ CYP2C19 and CYP2D6 assays. Cell Notes (2006) 14:20-24. Includes a discussion of CYP2D6 and -2C19 luminogenic substrate selectivity.
28. GUO Y, WANG Y, SI D, FAWCETT PJ, ZHONG D, ZHOU H: Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica (2005) 35(9):853-861.
29. ANZENBACHEROVA E, VEINLICHOVA A, MASEK V ANZENBACHER P: Comparison of 'high throughput' micromethods for determination of cytochrome P450 activities with classical methods using HPLC for product identification. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. (2005) 149(2):353-355.
30. UENG Y-F, KUWABARA T, CHUN Y-J, GUENGERICH FP: Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry (1997) 36:370-381.
31. NAKAJIMA M, INOUE T, SHIMADA N, TOKUDOME S, YAMAMOTO T, KUROIWA Y: Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. Drug Metab. Dispos. (1998) 26(3):261-266.
32. WHITLOCK JP: Induction of cytochrome P4501A1. Ann. Rev. Pharmacol. Toxicol. (1999) 39:103-125.
33. HALL MP, GRUBER MG, HANNAH RR, JENNENS-CLOUGH ML, WOOD KV: Stabilization of firefly luciferase using directed evolution. In: Bioluminescence and Chemiluminescence: Perspectives for the 21st Century. A Rode, M Pazzagli, LJ Kricka, PE Stanley (Eds.), John Wiley & Sons, Chichester (1998):392-395.
34. MANCY A, ANTIGNAC M, MINOLETTI C et al.: Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry (1999) 38:14264-14270.
35. GRANVIL CP, KRAUSZ KW, GELBOIN HV, IDLE JR, GONZALEZ FJ: 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. J. Pharmacol. Exp. Ther. (2002) 301(3):1025-1032.
36. STRESSER DM, BLANCHARD AP, TURNER SD et al.: Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab. Dispos. (2000) 28(12):1440-1448.
37. OBACH RS: Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab. Dispos. (1997) 25(12):1359-1369.
38. AUSTIN RP, BARTON P, MOHMED S, RILEY RJ: The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab. Dispos. (2005) 33(3):419-425.
39. ZHANG J-H, CHUNG TDY, OLDENBURG KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Scr. (1999) 4:67-73. A quantitative approach for measuring assay quality.
40. BOSETTI A, SOBOL S, MA D, GOOD T, LIU D, CALI JJ: Bioluminescent cytochrome P450 assays. Pbarmacologyonline (2005) 3:9-18.
41. WANG RW, NEWTON DJ, LIU N, ATKINS WM, LU AYH: Human cytochrome P450 3A4: in vitro drug-drug interactions patterns are substrate-dependent. Drug Metab. Dispos. (2000) 28(3):360-366.
42. HOSEA NA, MILLER GP, GUENGERICH FP: Elucidation of distinct binding sites for cytochrome P450 3A4. Biochemistry (2000) 39:5929-5939.
43. HUTZLER JM, HAUER MJ, TRACY TS: Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. Drug Metab. Dispos. (2001) 29(7):1029-1034.
44. KERDPIN O, ELLIOT DJ, BOYE SL, BIRKETT DJ, YOOVATHAWORN K, MINERS JO: Differential contributions of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity. Biochemistry (2004) 43(24):7834-7842.
45. DOMANSKI TL, HE Y-A, KHAN KK, ROUSSEL F, WANG Q, HALPERT JR: Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry (2001) 40:10150-10160.
46. TESTINA SA Jr, PATONAY G: High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. (2003) 30(5):1459-1467.
47. WEAVER R, GRAHAM KS, BEATTIE IG, RILEY RJ: Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab. Dispos. (2003) 31(7):955-966.
48. MOODY GC, GRIFFIN SJ, MATHER AN, MCGINNITY DF, RILEY RJ: Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica (1999) 29(1):53-75.
49. DELAPORTE E, SLAUGHTER DE, EGAN MA et al.: The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach. J. Biomol. Screen. (2001) 6(4):225-231.
50. NAKAMURA K, HANNA IH, CAI H, NISHIMURA Y, WILLIAMS KM, GUENGERICH FP: Coumarin substrates for cytochrome P450 2D6 fluorescence assays. Anal. Biochem. (2001) 292:280-286.
51. REINERS JJ, CANTU AR, PAVONE A, SMITH SC, GARDNER CR, LASKIN DL: Fluorescnece assay for per-cell estimation of cytochrome P450-dependent monooxygenase activitities in keratinocyte suspensions and cultures. Anal. Biochem. (1990) 188:317-324.
52. SPORTSMAN JR, LEE SK, DILLEY H, BUKAR R: Fluorescence polarization. High throughput screening: the discovery of bioactive substances. JP Devlin (Ed.), Marcel Dekker, Inc. New York, NY, USA (1997):389-399.
53. SINGH P, LILLYWHITE B, BANNAGHAN C, BROAD P: Using IMAP technology to identify kinase inhibitors: comparison with a substrate depletion approach and analysis of the nature of false positives. Comb. Chem. High Throughput Screen. (2005) 8(4):319-325.
54. SAI Y, DAI R, YANG TJ et al.: Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica (2000) 30(4):327-343.
55. CHANG TKH, GONZALEZ FJ, WAXMAN DJ: Evaluation of triaceryloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch. Biochem. Biophys. (1994) 311(2):437-442.
56. STRESSER DM, BROUDY MI, HO T et al.: Highly selective inhibition of human CYP3A in vitro by azamulin and evidence that inhibition is irreversible. Drug Metab. Dispos. (2004) 32(1):105-112.
57. OLESEN OV, LINNET K: Fluvoxamine-clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. J. Clin. Psychopharmacol. (2000) 20(1):35-42.
58. CRESPI CL, MILLER VP, PENMAN BW: Microtiter plate assays for inhibition of human, drug-metabolizing cytochrome P450. Anal. Biochem. (1997) 248:188-190.
59. 50. J. Biomol. Screen. (2002) 7(4):373-382.
60. YIN H, RACHA J, LI S-Y, OLEJNIK N, SATOH H, MOORE D: Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: application in CYP inhibition evaluation. Xenobiotica (2000) 30(2):141-154.
61. ATTAR M, DONG D, LING K-HJ, TANG-LIU DD-S: Cytochrome P450 2C8 and flavin-containing monooxygenases are involved in the metabolism of tazarotenic acid in humans. Drug Metab. Dispos. (2003) 31(4):476-481.
62. WEN X, WANG J-S, BACKMAN JT, LAITILA J, NEUVONEN PJ: Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab. Dispos. (2002) 30(6):631-635.
63. BACK DJ, TJIA JF, KARBWANG J COLBERT J: In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azotes, sulphonamides and quinolines. Br. J. Clin. Pharm. (1988) 26:23-29.
64. WEAVER R, GRAHAM KS, BEATTIE IG, RILEY RJ: Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab. Dispos. (2003) 31(7):955-966.
65. YAMAZAKI H, SUZUKI M, TANE K, SHIMADA N, NAKAJIMA M, YOKOI T: In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica (2000) 30(1):61-70.
66. DESTA Z, SOUKHOVA NV, FLOCKHART DA: Inhibition of cytochrome P450 (CYP450 isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob. Agents Chemother. (2001) 45(2):382-392.
67. LIU KH, KIM MJ, SHON JH et al.: Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro. Xenobiotica (2005) 35(1):27-38.
68. YAMAMOTO T, SUZUKI A, KOHNO Y: High-throughput screening to estimate single or multiple enzymes involved in drug metabolism: microtitre plate assay using a combination of recombinant CYP2D6 and human liver microsomes. Xenobiotica (2003) 33(8):823-839.
69. MARTINEZ C, AGUNDEZ JAG, GERVASINI G, MARTIN R, BENITEZ J: Tryptamine: a possible endogenous substrate for CYP2D6. Pharmacogenetics (1997) 7:85-93.
70. KARIV I, FERESHTEH MP, OLDENBURG KR: Development of a miniaturized 384-well high throughput screen for detection of substrates of cytochrome P450 2D6 and 3A4 metabolism. J. Biomol. Screen. (2001) 6(2):91-99.
71. DELAPORTE E, SLAUGHTER DE, EGAN MA et al.: The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach. J. Biomol. Screen. (2001) 6(4):225-231.
72. MA B, PRUEKSARITANONT T, LIN JH: Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab. Dispos. (2000) 28(2):125-130.
73. RACHA JK, ZHAO ZS, OLEJNIK N et al.: Substrate dependent inhibition profiles of fourteen drugs on CYP3A4 activity measured by a high throughput LCMS/MS method with four probe drugs, midazolam, testosterone, nifedipine and terfenadine. Drug Metab. Pharmacokinet. (2003) 18(2):128-138.
74. KENWORTHY KE, BLOOMER JC, CLARKE SE, HOUSTON JB: CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br. J. Clin. Pharmacol. (1999) 48:716-727.
75. RILEY RJ, PARKER AJ, TRIGG S, MANNERS CN: Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery. Pharm. Res. (2001) 18(5):652-655.
76. KALGUTKAR AS, TAYLOR TJ, VENKATAKRISHNAN K, ISIN EM: Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab. Dispos. (2003) 31(3):243-249.
77. SHEN L, FITZLOFF JF, COOK CS: Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As. Drug Metab. Dispos. (2004) 32(2):186-196.
78. EKINS S, STRESSER DM, WILLIAMS JA: In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol. Sci. (2003) 24(4):161-166.
79. http://www.gicare.com/pated/cimetidine.htm Jackson Gastroenterology Patient ed. (1998).
80. http://www.promega.com/ Technical Resources, Promega Corp. website, see Technical Bulletin #325. Detailed luminogenic CYP assay protocols.
81. http://www.promega.com/ Technical Resources, Promega Corp. website, see Technical Bulletin #340. Detailed luminogenic CYP assay protocols.
82. http://www.invitrogen.com/content/sfs/man uals/O-13873-rl%20US%200405.pdf Vivid CYP450 screening kit protocols.
83. http://www.bdbiosciences.com/discovery_lab ware/gentest Instruction manuals for high throughput P450 kits.
84. http://www.bdbioscicnces.com/discovery_lab ware/gentest/products/pdf/ postindx.shtml STRESSER DM, TURNER SD, ACKERMANN JM, MILLER VP, CRESPI CL: Fluorometric cytochromes P450 2C8, 2C9, and 2C19 inhibition assays: testing the one substrate paradigm. Poster.